Cat. No. FLP100004



## **PRODUCT INFORMATION**

CLDN6 **Target** 

Claudin 6; Claudin-6; Skullin; Claudin 6 **Synonyms** 

Human Claudin-6 full length protein membrane **Description** 

nanoparticles (MNPs)

**Delivery** In Stock **Uniprot ID** P56747 **Expression Host HEK293** 

**Protein Families** Transmembrane

Cell adhesion molecules (CAMs), Leukocyte **Protein Pathways** transendothelial migration, Tight junction

The human full length CLDN6 Protein has a MW of **Molecular Weight** 

23 kDa

Lyophilized from sterile PBS, pH 7.4. Normally 5 % – 8% trehalose is added as protectants before Formulation & lyophilization. Please see Certificate of Analysis Reconstitution

for specific instructions of reconstitution. Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not

intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Storage & Shipping

Lyophilized proteins are shipped at ambient

temperature.

Tight junctions represent one mode of cell-to-cell adhesion in epithelial or endothelial cell sheets, forming continuous seals around cells and serving as a physical barrier to prevent solutes and water from passing freely through the paracellular space. These junctions are comprised of sets of continuous networking strands in the outwardly facing cytoplasmic leaflet, with complementary grooves in the inwardly facing extracytoplasmic


leaflet. This gene encodes a component of tight junction strands, which is a member of the claudin family. The protein is an integral membrane protein and is one of the entry cofactors for hepatitis C virus. The gene methylation may be involved in esophageal tumorigenesis. This gene is adjacent to another family member CLDN9 on chromosome 16.

> Email: info@dimabio.com Website: www.dimabio.com

**Usage** Research use only

Conjugate Unconjugated

**Background** 







## ELISA assay to evaluate CLDN6-MNPs 0.5μg Human CLDN6-MNPs per well




Figure 1. Elisa plates were pre-coated with 0.5μg/per well purified human CLDN6 full length membrane nanoparticles. Serial diluted anti-CLDN6 monoclonal antibody (BME100082) solutions were added, washed, and incubated with secondary antibody before Elisa reading. From above data, the EC50 for anti-CLDN6 monoclonal antibody binding with CLDN6 full length membrane nanoparticles is 34.36ng/ml.




Figure 2. FACS analysis of CLDN6 MNPs

A. Negative Control 1: CLDN6 full length membrane nanoparticles samples were stained only with Goat anti-human IgG 488

secondary antibody.

B. Negative Control 2: Control membrane nanoparticles samples were stained with anti-CLDN6 antibody (BME100082) at 2µg/mL, followed by Goat anti-human IgG 488 secondary antibody.

C. Negative Control 3: CLDN6 full length membrane nanoparticles samples were stained with anti-GPRC5D antibody (an increase of the control of the cont

irrelevant antibody) at 2µg/mL, followed by Goat anti-human IgG 488 secondary antibody. D. CLDN6 full length membrane nanoparticles samples were stained with anti-CLDN6 antibody (BME100082) at 2µg/mL, followed by Goat anti-human IgG 488 secondary antibody.

Email: info@dimabio.com

Website: www.dimabio.com

